aluates Reports

$ 0.0

Automative

Global Oligonucleotide CDMO Market Research Report 2025

Published Date: January 2025

Report Code: QYRE-Auto-10N18969

BUY CHAPTERS

Global Oligonucleotide CDMO Market Research Report 2025

Code: QYRE-Auto-10N18969

Report

January 2025

Pages:110

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Companies

Agilent

ST Pharm

Bachem

Biospring

Creative Biogene

Sylentis

Ajinomoto Bio-Pharma

EUROAPI

Veliter

PolyPeptide Group

CordenPharma

Thermofischer

Bio Basic

GenScript

Cytiva

ScinoPharm

CBL

Piramal Pharma

CPC Scientific

Eurogentec S.A

Cambrex

WuXi STA

Oligonucleotide CDMO Market Size

The global market for Oligonucleotide CDMO was valued at US$ 1250 million in the year 2024 and is projected to reach a revised size of US$ 2839 million by 2031, growing at a CAGR of 12.5% during the forecast period.

Oligonucleotide CDMO Market

An Oligonucleotide CDMO (Contract Development and Manufacturing Organization) specializes in providing outsourced services related to the development and manufacturing of oligonucleotides. Oligonucleotides are short DNA or RNA molecules used for a variety of applications, including in genetic research, diagnostics, and therapeutics. These organizations are key players in the biopharmaceutical industry, helping companies bring oligonucleotide-based products from the research stage to commercialization.

North American market for Oligonucleotide CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Oligonucleotide CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Oligonucleotide CDMO in Pharmaceutical and Biotechnology Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Oligonucleotide CDMO include Agilent, ST Pharm, Bachem, BioSpring, Creative Biogene, Sylentis, Ajinomoto Bio-Pharma, EUROAPI, Veliter, PolyPeptide Group, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Oligonucleotide CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide CDMO.

The Oligonucleotide CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oligonucleotide CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Oligonucleotide CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Oligonucleotide CDMO Market Report

Report Metric	Details
Report Name	Oligonucleotide CDMO Market
Accounted market size in year	US$ 1250 million
Forecasted market size in 2031	US$ 2839 million
CAGR	12.5%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	APIs and Intermediates FDF
Segment by Application	Pharmaceutical and Biotechnology Companies Research Institutes Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Agilent, ST Pharm, Bachem, BioSpring, Creative Biogene, Sylentis, Ajinomoto Bio-Pharma, EUROAPI, Veliter, PolyPeptide Group, CordenPharma, Thermofischer, Bio Basic, Genscript, Cytiva, ScinoPharm, CBL, Piramal Pharma, CPC Scientific, Eurogentec, Cambrex, WuXi STA
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oligonucleotide CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Oligonucleotide CDMO Market growing?

Ans: The Oligonucleotide CDMO Market witnessing a CAGR of 12.5% during the forecast period 2025-2031.

What is the Oligonucleotide CDMO Market size in 2031?

Ans: The Oligonucleotide CDMO Market size in 2031 will be US$ 2839 million.

Who are the main players in the Oligonucleotide CDMO Market report?

Ans: The main players in the Oligonucleotide CDMO Market are Agilent, ST Pharm, Bachem, BioSpring, Creative Biogene, Sylentis, Ajinomoto Bio-Pharma, EUROAPI, Veliter, PolyPeptide Group, CordenPharma, Thermofischer, Bio Basic, Genscript, Cytiva, ScinoPharm, CBL, Piramal Pharma, CPC Scientific, Eurogentec, Cambrex, WuXi STA

What are the Application segmentation covered in the Oligonucleotide CDMO Market report?

Ans: The Applications covered in the Oligonucleotide CDMO Market report are Pharmaceutical and Biotechnology Companies, Research Institutes, Others

What are the Type segmentation covered in the Oligonucleotide CDMO Market report?

Ans: The Types covered in the Oligonucleotide CDMO Market report are APIs and Intermediates, FDF

Recommended Reports

CDMO Services

Oligonucleotide and Related

Biopharmaceutical CDMO

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Oligonucleotide CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 APIs and Intermediates

1.2.3 FDF

1.3 Market by Application

1.3.1 Global Oligonucleotide CDMO Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Pharmaceutical and Biotechnology Companies

1.3.3 Research Institutes

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Oligonucleotide CDMO Market Perspective (2020-2031)

2.2 Global Oligonucleotide CDMO Growth Trends by Region

2.2.1 Global Oligonucleotide CDMO Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Oligonucleotide CDMO Historic Market Size by Region (2020-2025)

2.2.3 Oligonucleotide CDMO Forecasted Market Size by Region (2026-2031)

2.3 Oligonucleotide CDMO Market Dynamics

2.3.1 Oligonucleotide CDMO Industry Trends

2.3.2 Oligonucleotide CDMO Market Drivers

2.3.3 Oligonucleotide CDMO Market Challenges

2.3.4 Oligonucleotide CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Oligonucleotide CDMO Players by Revenue

3.1.1 Global Top Oligonucleotide CDMO Players by Revenue (2020-2025)

3.1.2 Global Oligonucleotide CDMO Revenue Market Share by Players (2020-2025)

3.2 Global Top Oligonucleotide CDMO Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Oligonucleotide CDMO Revenue

3.4 Global Oligonucleotide CDMO Market Concentration Ratio

3.4.1 Global Oligonucleotide CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide CDMO Revenue in 2024

3.5 Global Key Players of Oligonucleotide CDMO Head office and Area Served

3.6 Global Key Players of Oligonucleotide CDMO, Product and Application

3.7 Global Key Players of Oligonucleotide CDMO, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Oligonucleotide CDMO Breakdown Data by Type

4.1 Global Oligonucleotide CDMO Historic Market Size by Type (2020-2025)

4.2 Global Oligonucleotide CDMO Forecasted Market Size by Type (2026-2031)

5 Oligonucleotide CDMO Breakdown Data by Application

5.1 Global Oligonucleotide CDMO Historic Market Size by Application (2020-2025)

5.2 Global Oligonucleotide CDMO Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Oligonucleotide CDMO Market Size (2020-2031)

6.2 North America Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Oligonucleotide CDMO Market Size by Country (2020-2025)

6.4 North America Oligonucleotide CDMO Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Oligonucleotide CDMO Market Size (2020-2031)

7.2 Europe Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Oligonucleotide CDMO Market Size by Country (2020-2025)

7.4 Europe Oligonucleotide CDMO Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Oligonucleotide CDMO Market Size (2020-2031)

8.2 Asia-Pacific Oligonucleotide CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Oligonucleotide CDMO Market Size by Region (2020-2025)

8.4 Asia-Pacific Oligonucleotide CDMO Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Oligonucleotide CDMO Market Size (2020-2031)

9.2 Latin America Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Oligonucleotide CDMO Market Size by Country (2020-2025)

9.4 Latin America Oligonucleotide CDMO Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Oligonucleotide CDMO Market Size (2020-2031)

10.2 Middle East & Africa Oligonucleotide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Oligonucleotide CDMO Market Size by Country (2020-2025)

10.4 Middle East & Africa Oligonucleotide CDMO Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Agilent

11.1.1 Agilent Company Details

11.1.2 Agilent Business Overview

11.1.3 Agilent Oligonucleotide CDMO Introduction

11.1.4 Agilent Revenue in Oligonucleotide CDMO Business (2020-2025)

11.1.5 Agilent Recent Development

11.2 ST Pharm

11.2.1 ST Pharm Company Details

11.2.2 ST Pharm Business Overview

11.2.3 ST Pharm Oligonucleotide CDMO Introduction

11.2.4 ST Pharm Revenue in Oligonucleotide CDMO Business (2020-2025)

11.2.5 ST Pharm Recent Development

11.3 Bachem

11.3.1 Bachem Company Details

11.3.2 Bachem Business Overview

11.3.3 Bachem Oligonucleotide CDMO Introduction

11.3.4 Bachem Revenue in Oligonucleotide CDMO Business (2020-2025)

11.3.5 Bachem Recent Development

11.4 BioSpring

11.4.1 BioSpring Company Details

11.4.2 BioSpring Business Overview

11.4.3 BioSpring Oligonucleotide CDMO Introduction

11.4.4 BioSpring Revenue in Oligonucleotide CDMO Business (2020-2025)

11.4.5 BioSpring Recent Development

11.5 Creative Biogene

11.5.1 Creative Biogene Company Details

11.5.2 Creative Biogene Business Overview

11.5.3 Creative Biogene Oligonucleotide CDMO Introduction

11.5.4 Creative Biogene Revenue in Oligonucleotide CDMO Business (2020-2025)

11.5.5 Creative Biogene Recent Development

11.6 Sylentis

11.6.1 Sylentis Company Details

11.6.2 Sylentis Business Overview

11.6.3 Sylentis Oligonucleotide CDMO Introduction

11.6.4 Sylentis Revenue in Oligonucleotide CDMO Business (2020-2025)

11.6.5 Sylentis Recent Development

11.7 Ajinomoto Bio-Pharma

11.7.1 Ajinomoto Bio-Pharma Company Details

11.7.2 Ajinomoto Bio-Pharma Business Overview

11.7.3 Ajinomoto Bio-Pharma Oligonucleotide CDMO Introduction

11.7.4 Ajinomoto Bio-Pharma Revenue in Oligonucleotide CDMO Business (2020-2025)

11.7.5 Ajinomoto Bio-Pharma Recent Development

11.8 EUROAPI

11.8.1 EUROAPI Company Details

11.8.2 EUROAPI Business Overview

11.8.3 EUROAPI Oligonucleotide CDMO Introduction

11.8.4 EUROAPI Revenue in Oligonucleotide CDMO Business (2020-2025)

11.8.5 EUROAPI Recent Development

11.9 Veliter

11.9.1 Veliter Company Details

11.9.2 Veliter Business Overview

11.9.3 Veliter Oligonucleotide CDMO Introduction

11.9.4 Veliter Revenue in Oligonucleotide CDMO Business (2020-2025)

11.9.5 Veliter Recent Development

11.10 PolyPeptide Group

11.10.1 PolyPeptide Group Company Details

11.10.2 PolyPeptide Group Business Overview

11.10.3 PolyPeptide Group Oligonucleotide CDMO Introduction

11.10.4 PolyPeptide Group Revenue in Oligonucleotide CDMO Business (2020-2025)

11.10.5 PolyPeptide Group Recent Development

11.11 CordenPharma

11.11.1 CordenPharma Company Details

11.11.2 CordenPharma Business Overview

11.11.3 CordenPharma Oligonucleotide CDMO Introduction

11.11.4 CordenPharma Revenue in Oligonucleotide CDMO Business (2020-2025)

11.11.5 CordenPharma Recent Development

11.12 Thermofischer

11.12.1 Thermofischer Company Details

11.12.2 Thermofischer Business Overview

11.12.3 Thermofischer Oligonucleotide CDMO Introduction

11.12.4 Thermofischer Revenue in Oligonucleotide CDMO Business (2020-2025)

11.12.5 Thermofischer Recent Development

11.13 Bio Basic

11.13.1 Bio Basic Company Details

11.13.2 Bio Basic Business Overview

11.13.3 Bio Basic Oligonucleotide CDMO Introduction

11.13.4 Bio Basic Revenue in Oligonucleotide CDMO Business (2020-2025)

11.13.5 Bio Basic Recent Development

11.14 Genscript

11.14.1 Genscript Company Details

11.14.2 Genscript Business Overview

11.14.3 Genscript Oligonucleotide CDMO Introduction

11.14.4 Genscript Revenue in Oligonucleotide CDMO Business (2020-2025)

11.14.5 Genscript Recent Development

11.15 Cytiva

11.15.1 Cytiva Company Details

11.15.2 Cytiva Business Overview

11.15.3 Cytiva Oligonucleotide CDMO Introduction

11.15.4 Cytiva Revenue in Oligonucleotide CDMO Business (2020-2025)

11.15.5 Cytiva Recent Development

11.16 ScinoPharm

11.16.1 ScinoPharm Company Details

11.16.2 ScinoPharm Business Overview

11.16.3 ScinoPharm Oligonucleotide CDMO Introduction

11.16.4 ScinoPharm Revenue in Oligonucleotide CDMO Business (2020-2025)

11.16.5 ScinoPharm Recent Development

11.17 CBL

11.17.1 CBL Company Details

11.17.2 CBL Business Overview

11.17.3 CBL Oligonucleotide CDMO Introduction

11.17.4 CBL Revenue in Oligonucleotide CDMO Business (2020-2025)

11.17.5 CBL Recent Development

11.18 Piramal Pharma

11.18.1 Piramal Pharma Company Details

11.18.2 Piramal Pharma Business Overview

11.18.3 Piramal Pharma Oligonucleotide CDMO Introduction

11.18.4 Piramal Pharma Revenue in Oligonucleotide CDMO Business (2020-2025)

11.18.5 Piramal Pharma Recent Development

11.19 CPC Scientific

11.19.1 CPC Scientific Company Details

11.19.2 CPC Scientific Business Overview

11.19.3 CPC Scientific Oligonucleotide CDMO Introduction

11.19.4 CPC Scientific Revenue in Oligonucleotide CDMO Business (2020-2025)

11.19.5 CPC Scientific Recent Development

11.20 Eurogentec

11.20.1 Eurogentec Company Details

11.20.2 Eurogentec Business Overview

11.20.3 Eurogentec Oligonucleotide CDMO Introduction

11.20.4 Eurogentec Revenue in Oligonucleotide CDMO Business (2020-2025)

11.20.5 Eurogentec Recent Development

11.21 Cambrex

11.21.1 Cambrex Company Details

11.21.2 Cambrex Business Overview

11.21.3 Cambrex Oligonucleotide CDMO Introduction

11.21.4 Cambrex Revenue in Oligonucleotide CDMO Business (2020-2025)

11.21.5 Cambrex Recent Development

11.22 WuXi STA

11.22.1 WuXi STA Company Details

11.22.2 WuXi STA Business Overview

11.22.3 WuXi STA Oligonucleotide CDMO Introduction

11.22.4 WuXi STA Revenue in Oligonucleotide CDMO Business (2020-2025)

11.22.5 WuXi STA Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Companies

Agilent

ST Pharm

Bachem

Biospring

Creative Biogene

Sylentis

Ajinomoto Bio-Pharma

EUROAPI

Veliter

PolyPeptide Group

CordenPharma

Thermofischer

Bio Basic

GenScript

Cytiva

ScinoPharm

CBL

Piramal Pharma

CPC Scientific

Eurogentec S.A

Cambrex

WuXi STA

List of Tables

Table 1. Global Oligonucleotide CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of APIs and Intermediates

Table 3. Key Players of FDF

Table 4. Global Oligonucleotide CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Oligonucleotide CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Oligonucleotide CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Oligonucleotide CDMO Market Share by Region (2020-2025)

Table 8. Global Oligonucleotide CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Oligonucleotide CDMO Market Share by Region (2026-2031)

Table 10. Oligonucleotide CDMO Market Trends

Table 11. Oligonucleotide CDMO Market Drivers

Table 12. Oligonucleotide CDMO Market Challenges

Table 13. Oligonucleotide CDMO Market Restraints

Table 14. Global Oligonucleotide CDMO Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Oligonucleotide CDMO Market Share by Players (2020-2025)

Table 16. Global Top Oligonucleotide CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide CDMO as of 2024)

Table 17. Ranking of Global Top Oligonucleotide CDMO Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Oligonucleotide CDMO Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Oligonucleotide CDMO, Headquarters and Area Served

Table 20. Global Key Players of Oligonucleotide CDMO, Product and Application

Table 21. Global Key Players of Oligonucleotide CDMO, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Oligonucleotide CDMO Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Oligonucleotide CDMO Revenue Market Share by Type (2020-2025)

Table 25. Global Oligonucleotide CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Oligonucleotide CDMO Revenue Market Share by Type (2026-2031)

Table 27. Global Oligonucleotide CDMO Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Oligonucleotide CDMO Revenue Market Share by Application (2020-2025)

Table 29. Global Oligonucleotide CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Oligonucleotide CDMO Revenue Market Share by Application (2026-2031)

Table 31. North America Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Oligonucleotide CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Oligonucleotide CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Oligonucleotide CDMO Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Oligonucleotide CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Oligonucleotide CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Oligonucleotide CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 46. Agilent Company Details

Table 47. Agilent Business Overview

Table 48. Agilent Oligonucleotide CDMO Product

Table 49. Agilent Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 50. Agilent Recent Development

Table 51. ST Pharm Company Details

Table 52. ST Pharm Business Overview

Table 53. ST Pharm Oligonucleotide CDMO Product

Table 54. ST Pharm Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 55. ST Pharm Recent Development

Table 56. Bachem Company Details

Table 57. Bachem Business Overview

Table 58. Bachem Oligonucleotide CDMO Product

Table 59. Bachem Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 60. Bachem Recent Development

Table 61. BioSpring Company Details

Table 62. BioSpring Business Overview

Table 63. BioSpring Oligonucleotide CDMO Product

Table 64. BioSpring Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 65. BioSpring Recent Development

Table 66. Creative Biogene Company Details

Table 67. Creative Biogene Business Overview

Table 68. Creative Biogene Oligonucleotide CDMO Product

Table 69. Creative Biogene Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 70. Creative Biogene Recent Development

Table 71. Sylentis Company Details

Table 72. Sylentis Business Overview

Table 73. Sylentis Oligonucleotide CDMO Product

Table 74. Sylentis Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 75. Sylentis Recent Development

Table 76. Ajinomoto Bio-Pharma Company Details

Table 77. Ajinomoto Bio-Pharma Business Overview

Table 78. Ajinomoto Bio-Pharma Oligonucleotide CDMO Product

Table 79. Ajinomoto Bio-Pharma Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 80. Ajinomoto Bio-Pharma Recent Development

Table 81. EUROAPI Company Details

Table 82. EUROAPI Business Overview

Table 83. EUROAPI Oligonucleotide CDMO Product

Table 84. EUROAPI Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 85. EUROAPI Recent Development

Table 86. Veliter Company Details

Table 87. Veliter Business Overview

Table 88. Veliter Oligonucleotide CDMO Product

Table 89. Veliter Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 90. Veliter Recent Development

Table 91. PolyPeptide Group Company Details

Table 92. PolyPeptide Group Business Overview

Table 93. PolyPeptide Group Oligonucleotide CDMO Product

Table 94. PolyPeptide Group Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 95. PolyPeptide Group Recent Development

Table 96. CordenPharma Company Details

Table 97. CordenPharma Business Overview

Table 98. CordenPharma Oligonucleotide CDMO Product

Table 99. CordenPharma Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 100. CordenPharma Recent Development

Table 101. Thermofischer Company Details

Table 102. Thermofischer Business Overview

Table 103. Thermofischer Oligonucleotide CDMO Product

Table 104. Thermofischer Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 105. Thermofischer Recent Development

Table 106. Bio Basic Company Details

Table 107. Bio Basic Business Overview

Table 108. Bio Basic Oligonucleotide CDMO Product

Table 109. Bio Basic Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 110. Bio Basic Recent Development

Table 111. Genscript Company Details

Table 112. Genscript Business Overview

Table 113. Genscript Oligonucleotide CDMO Product

Table 114. Genscript Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 115. Genscript Recent Development

Table 116. Cytiva Company Details

Table 117. Cytiva Business Overview

Table 118. Cytiva Oligonucleotide CDMO Product

Table 119. Cytiva Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 120. Cytiva Recent Development

Table 121. ScinoPharm Company Details

Table 122. ScinoPharm Business Overview

Table 123. ScinoPharm Oligonucleotide CDMO Product

Table 124. ScinoPharm Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 125. ScinoPharm Recent Development

Table 126. CBL Company Details

Table 127. CBL Business Overview

Table 128. CBL Oligonucleotide CDMO Product

Table 129. CBL Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 130. CBL Recent Development

Table 131. Piramal Pharma Company Details

Table 132. Piramal Pharma Business Overview

Table 133. Piramal Pharma Oligonucleotide CDMO Product

Table 134. Piramal Pharma Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 135. Piramal Pharma Recent Development

Table 136. CPC Scientific Company Details

Table 137. CPC Scientific Business Overview

Table 138. CPC Scientific Oligonucleotide CDMO Product

Table 139. CPC Scientific Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 140. CPC Scientific Recent Development

Table 141. Eurogentec Company Details

Table 142. Eurogentec Business Overview

Table 143. Eurogentec Oligonucleotide CDMO Product

Table 144. Eurogentec Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 145. Eurogentec Recent Development

Table 146. Cambrex Company Details

Table 147. Cambrex Business Overview

Table 148. Cambrex Oligonucleotide CDMO Product

Table 149. Cambrex Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 150. Cambrex Recent Development

Table 151. WuXi STA Company Details

Table 152. WuXi STA Business Overview

Table 153. WuXi STA Oligonucleotide CDMO Product

Table 154. WuXi STA Revenue in Oligonucleotide CDMO Business (2020-2025) & (US$ Million)

Table 155. WuXi STA Recent Development

Table 156. Research Programs/Design for This Report

Table 157. Key Data Information from Secondary Sources

Table 158. Key Data Information from Primary Sources

Table 159. Authors List of This Report

List of Figures

Figure 1. Oligonucleotide CDMO Picture

Figure 2. Global Oligonucleotide CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Oligonucleotide CDMO Market Share by Type: 2024 VS 2031

Figure 4. APIs and Intermediates Features

Figure 5. FDF Features

Figure 6. Global Oligonucleotide CDMO Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Oligonucleotide CDMO Market Share by Application: 2024 VS 2031

Figure 8. Pharmaceutical and Biotechnology Companies Case Studies

Figure 9. Research Institutes Case Studies

Figure 10. Others Case Studies

Figure 11. Oligonucleotide CDMO Report Years Considered

Figure 12. Global Oligonucleotide CDMO Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Oligonucleotide CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Oligonucleotide CDMO Market Share by Region: 2024 VS 2031

Figure 15. Global Oligonucleotide CDMO Market Share by Players in 2024

Figure 16. Global Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 17. The Top 10 and 5 Players Market Share by Oligonucleotide CDMO Revenue in 2024

Figure 18. North America Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Oligonucleotide CDMO Market Share by Country (2020-2031)

Figure 20. United States Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Oligonucleotide CDMO Market Share by Country (2020-2031)

Figure 24. Germany Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Oligonucleotide CDMO Market Share by Region (2020-2031)

Figure 32. China Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Oligonucleotide CDMO Market Share by Country (2020-2031)

Figure 40. Mexico Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Oligonucleotide CDMO Market Share by Country (2020-2031)

Figure 44. Turkey Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Oligonucleotide CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Agilent Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 48. ST Pharm Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 49. Bachem Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 50. BioSpring Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 51. Creative Biogene Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 52. Sylentis Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 53. Ajinomoto Bio-Pharma Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 54. EUROAPI Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 55. Veliter Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 56. PolyPeptide Group Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 57. CordenPharma Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 58. Thermofischer Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 59. Bio Basic Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 60. Genscript Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 61. Cytiva Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 62. ScinoPharm Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 63. CBL Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 64. Piramal Pharma Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 65. CPC Scientific Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 66. Eurogentec Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 67. Cambrex Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 68. WuXi STA Revenue Growth Rate in Oligonucleotide CDMO Business (2020-2025)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Plasmid DNA CDMO Service Market Research Report 2024

Global Aptamer CDMO Market Research Report 2024

Global Cell and Gene Therapy CDMO Services Market Research Report 2024

Global Chemical CDMO Market Research Report 2024

Global mRNA CDMO Service Market Research Report 2024

Global Biopharmaceutical CDMO Market Research Report 2025

Global Viral Vector Manufacturing CDMO Services Market Research Report 2024

Global Biopharmaceutical and Bio CDMO Market Research Report 2024

Global Biopharmaceutical CDMO Service Market Research Report 2024

Global Small Molecules CDMO Services Market Research Report 2024

Small Molecule Drug CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Pharmaceutical CDMO Market Research Report 2025

Global Pharmaceutical Contract Development and Manufacturing Organization Market Research Report 2025

Global Lipid Nanoparticle CDMO Market Research Report 2025

Global Bio Contract Development and Manufacturing Organizations CDMOs Market Insights Forecast to 2030

Global Full Service CDMO Market Research Report 2024

CGT CDMO Market

Global Contract Dose Manufacturing Market Insights Forecast to 2030

Global Small Molecule Drug CDMO Services Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions